Nasus Pharma Announces Enrollment and Dosing of First Patient in Phase 1 Study of NS003 Intranasal Formulation of Ondansetron
Nasus Pharma dosed the first patient in a Phase 1 pharmacokinetic trial of NS003, its intranasal powder formulation of ondansetron for CINV and PONV. Pre-clinical data showed a PK profile comparable to IV ondansetron and a favorable safety profile at four times the test dose.
Key figures
- Drug Name
- NS003 (intranasal powder ondansetron)
- Phase Of Trial
- Phase 1
- Indications
- chemotherapy-induced nausea and vomiting (CINV), post-operative nausea and vomiting (PONV)
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.